Hematologic Oncology

A supplemental Biologics License Application has been submitted to the FDA for brentuximab vedotin (Adcetris) as a treatment for patients with cutaneous T-cell lymphoma (CTCL), according to Seattle Genetics, which codevelops the antibody-drug conjugate with Takeda.

Lisa G. Roth, MD, discusses the challenges of treating adolescent and young adult patients with Hodgkin lymphoma and the benefits of having a multidisciplinary approach with this population.

Seattle Genetics has stopped the phase III CASCADE trial of frontline vadastuximab talirine (SGN-CD33A) for patients with acute myeloid leukemia following a recommendation from an independent data monitoring committee.

Tsiporah B. Shore, MD, discusses some of these newer advancements related to stem cell transplantation and the challenges with including patients in ethnic populations.

Treatment with rituximab (Rituxan) plus lenalidomide (Revlimid) followed by maintenance therapy demonstrated promising clinical activity for patients with relapsed/refractory indolent non-Hodgkin's lymphoma, according to findings from the phase IIIb MAGNIFY study.

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the TRANSCEND study, which is exploring the CD19-directed chimeric antigen receptor (CAR) T-cell therapy JCAR017 in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Treatment with JCAR017 demonstrated a complete response rate of 59% and an objective response rate of 86% for patients with relapsed or refractory diffuse large B-cell lymphoma.

Chan Cheah, MD, University of Western Australia, discusses treatment for patients with nodular lymphocyte predominant Hodgkin lymphoma.

Angelo Fama, MD, Division of Hematology, Mayo Clinic, discusses a case control study of the GB Virus-C (GBV-C) infection and the risk of lymphoma.

Combining pembrolizumab with rituximab induced a high response rate in patients with relapsed follicular lymphoma.

Copanlisib showed an objective response rate of 59.2% without inducing major colitis events or elevation of hepatic transaminases in patients with relapsed or refractory indolent B-cell lymphoma.

At more than 40 months’ follow-up, combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 32% versus rituximab plus chemotherapy in patients with follicular lymphoma.

Combining the novel BTK inhibitor BGB-3111 with the CD-20 antibody obinutuzumab demonstrated clinical activity and was well tolerated in patients with chronic lymphocytic leukemia/small lymphocytic leukemia or follicular lymphoma.

Avelumab (Bavencio) demonstrated clinical activity and an acceptable safety and tolerability profile in heavily pretreated patients with classical Hodgkin lymphoma.

Clemens A. Schmitt, MD, director and professor at Berlin School of Integrative Oncology, discusses a conceptually novel treatment approach to classical Hodgkin lymphoma.

Copanlisib (BAY 80-6946), a novel PI3K inhibitor, is being combined with standard rituximab-based regimens in patients with relapsed, indolent non-Hodgkin lymphoma.

High levels of response were observed with nivolumab (Opdivo), regardless of previous treatment with brentuximab vedotin (Adcetris), in patients with relapsed/refractory Hodgkin lymphoma after autologous stem-cell transplant.

Pembrolizumab (Keytruda) demonstrated antitumor activity in the majority of patients with recurrent/refractory primary mediastinal large B-cell lymphoma.

Although FLT3 mutations are well established as a prognostic marker in patients with AML, efforts to target the aberration therapeutically were underway for more than 15 years before yielding success.

Sarah Rutherford, MD, discusses rare DLBCL subtypes, ongoing research to improve outcomes for these patient populations, and the potential role of CAR T-cell therapy.

Constantine S. Tam, MD, discusses phase III PCYC-1143 trial is investigating the combination of ibrutinib and venetoclax as well as the next steps with venetoclax /ibrutinib and other rational combinations in MCL.

Tisagenlecleucel-T (CTL019) met its primary endpoint for best objective response rate in patients with relapsed or refractory diffuse large B-cell lymphoma.

Connie Batlevi, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses safety results of a phase I study evaluating the combination of ibrutinib (Imbruvica) and buparlisib in patients with mantle cell lymphoma (MCL), follicular lymphoma (FL), and diffuse large B-cell lymphoma (DLBCL).

Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.

Constantine S. Tam, MD, associate professor, Peter MacCullum Cancer Centre, discusses the phase II and phase III studies investigating the combination of ibrutinib (Imbruvica) plus venetoclax (Venclexta) for patients with mantle cell lymphoma (MCL).